Dasatinib.
Kantarjian
Hagop
H
Jabbour
Elias
E
Grimley
Joanne
J
Kirkpatrick
Peter
P
D000284:Administration, Oral; D000328:Adult; D002986:Clinical Trials as Topic; D000069439:Dasatinib; D017277:Drug Approval / Q000379:methods; D019983:Guideline Adherence / Q000592:standards; D006801:Humans; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000188:drug therapy; D015394:Molecular Structure; D054198:Precursor Cell Lymphoblastic Leukemia-Lymphoma / Q000188:drug therapy; D047428:Protein Kinase Inhibitors / Q000008:administration & dosage / Q000737:chemistry / Q000627:therapeutic use*; D011743:Pyrimidines / Q000008:administration & dosage / Q000737:chemistry / Q000627:therapeutic use*; D013844:Thiazoles / Q000008:administration & dosage / Q000737:chemistry / Q000627:therapeutic use*; D016896:Treatment Outcome
D047428:Protein Kinase Inhibitors; D011743:Pyrimidines; D013844:Thiazoles; D000069439:Dasatinib